Alzheimer; News from the web:

In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.

Read all about it HERE